S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Brain Tumors, Gastric Cancer, Ovarian Cancer
About this trial
This is an interventional treatment trial for Brain Tumors focused on measuring stage II gastric cancer, stage III gastric cancer, stage IV gastric cancer, recurrent gastric cancer, adenocarcinoma of the prostate, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, recurrent adult brain tumor, stage IV prostate cancer, recurrent prostate cancer, adult anaplastic astrocytoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of one the following: Stage II-IV gastric cancer Stage IIC-IV ovarian cancer in first complete remission CA 125 normal and stable* Grade III anaplastic astrocytoma Stage IV (M1) prostate adenocarcinoma No small cell variations No biochemical progression after definitive surgery, defined by the following: Prostate-specific antigen more than 0.4 ng/mL which remains elevated on 2 additional measurements at least 2 weeks apart after prostatectomy Three consecutive rises in PSA, each at least 1 month apart after definitive radiotherapy Must be receiving androgen blockade PSA less than 5 ng/mL and stable* Documented EGFRvIII expression in primary tumor Must have received prior surgery and or chemoradiotherapy for disease (except prostate cancer patients) NOTE: *Stable defined as no increase over 2 measurements at least 28 days apart with the last measurement within the past 28 days PATIENT CHARACTERISTICS: Age: 80 and under Performance status: Zubrod 0 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL Hepatic: SGOT no greater than 2.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN No hepatitis Renal: Not specified Other: No other malignancy in the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission No contraindication to receiving sargramostim (GM-CSF) or KLH-based vaccine products No autoimmune disease HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 1 month since prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy: See Disease Characteristics At least 1 month since prior treatment dose corticosteroids No concurrent corticosteroids Radiotherapy: See Disease Characteristics No concurrent radiotherapy Surgery: See Disease Characteristics Other: Recovered from all prior therapies No concurrent enrollment on other phase I studies No other concurrent immune modulators
Sites / Locations
- Bay Regional Medical Center
- Mercy Regional Cancer Center at Mercy Hospital
- St. Joseph Hospital Community Cancer Center
- Olympic Hematology and Oncology
- Skagit Valley Hospital Cancer Care Center
- Fred Hutchinson Cancer Research Center
- Harborview Medical Center
- Group Health Central Hospital
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
- University Cancer Center at University of Washington Medical Center
- North Puget Oncology at United General Hospital
- Cancer Care Northwest - Spokane South
- Wenatchee Valley Clinic
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
EGFR vaccine with GMCSF
EGFR vaccine with KLH
EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m